Mechanism of Nebivolol's Effect on Coronary Flow Reserve in Coronary Microvascular Dysfunction

Guideline Recommendations for Beta-Blockers in CMD

• The American Heart Association and European Society of Cardiology recommend beta-blockers as first-line antianginal therapy for coronary microvascular disease with reduced coronary flow reserve (CFR) and/or elevated index of microvascular resistance (IMR) (≥25) 1, 2, 3
• The American College of Cardiology suggests that the mechanism of benefit relates to slowing heart rate, which increases diastolic time and coronary perfusion, particularly important given microvascular dysfunction 4, 5
• Beta-blockers are preferred in CMD patients with evidence of increased adrenergic activity, according to the European Society of Cardiology 4, 5

Contraindications and Caveats

• Beta-blockers are absolutely contraindicated in vasospastic angina, as they can precipitate spasm by leaving α-mediated vasoconstriction unopposed, as stated by the American Heart Association and European Society of Cardiology 1, 4, 5

Patient Selection and Treatment

• The European Society of Cardiology recommends considering nebivolol specifically in CMD patients with documented reduced CFR (<2.5) and/or elevated IMR (≥25) on invasive coronary function testing 1, 3, 6
• The American College of Cardiology suggests ensuring absence of vasospastic component through acetylcholine testing, as beta-blockade is contraindicated if epicardial or microvascular spasm is present 1, 3

Dosing Strategy

• The European Heart Journal recommends starting with nebivolol 5 mg once daily and targeting resting heart rate of 55-60 beats per minute, consistent with guideline recommendations for beta-blocker therapy in CMD 2

Combination Therapy Considerations

• The American College of Cardiology suggests that nebivolol can be combined with ACE inhibitors, which improve endothelium-dependent vasodilation and are recommended baseline therapy for CMD 1, 3
• The Journal of the American College of Cardiology recommends adding ranolazine or nicorandil for refractory microvascular spasm symptoms 1, 3
• The European Heart Journal advises avoiding combining with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) due to additive negative chronotropic effects 2